Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Paul Fronstin, director of health benefits research at EBRI, recently explained to MHE editors how health benefits are changing and why it's important.
Today, it's a challenge for employers to design health plans that encourage people to pick better, high-value care.
Fronstin
Fronstin shared that a major step forward was a 2019 IRS rule that allowed some health services to skip deductibles in HSA plans, making them more accessible.
He also discussed high-deductible health plans (HDHPs), which, initially, these plans made people use less healthcare, but over time, they don’t really save much money.
People with HSAs often "treat them like spending accounts" instead of saving for future healthcare, which can impact how they make decisions, according to Fronstin.
He added that more big companies are self-insuring because it keeps benefits consistent across states, though some gaps, such as IVF coverage, still exist.
Fronstin also believes technology such as AI and mobile apps will help employees better understand their health plans and make smarter choices during open enrollment.
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
In our latest "Meet the Board" podcast episode, Managed Healthcare Executive Editors caught up with editorial advisory board member, Eric Hunter, CEO of CareOregon, to discuss a number of topics, one including the merger that never closed with SCAN Health Plan due to local opposition from Oregonians.
Listen
FDA Approves First-Ever Cell Therapy Treatment for Rare Progressive Eye Disease
March 20th 2025Encelto is small, semi-permeable capsule implanted in the eye that contains allogeneic retinal pigment epithelium cells genetically engineered to produce specific therapeutic proteins. It will be available in June 2025.
Read More
